Key facts
- This page summarizes Kimberly Manhard's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Apr 2023, 17:26.
Kimberly Manhard - 13 Apr 2023 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)
- Reporting relationship
- EVP, Drug Development
- Issuer ticker
- HRTX
- Reported as of
- 13 Apr 2023
- Net transaction value
- -$4,081
- SEC form
- 4
- Accepted by SEC
- 17 Apr 2023, 17:26:14 UTC
- Prior SEC filing
- 20 Jan 2023
- Next SEC filing
- 30 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa Peraza Attorney-in-fact for Kimberly Manhard
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kimberly Manhard filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 17 Apr 2023.
Change
- Previous filing in this sequence was filed on 20 Jan 2023.
- Current net transaction value: -$4,081.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HRTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,250
- Change %
- +5.2%
- Price
- Shares after
- 25,183
- Date
- 13 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
HRTX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,564
- Change %
- +18%
- Price
- Shares after
- 29,747
- Date
- 13 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
HRTX
transaction
Common Stock
Tax liability
- Transaction value
- $4,081
- Shares
- -1,417
- Change %
- -4.8%
- Price
- $2.88
- Shares after
- 28,330
- Date
- 13 Apr 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HRTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,250
- Change %
- -14%
- Price
- $0.000000
- Shares after
- 7,500
- Date
- 13 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,250
- Exercise price
- Footnotes
- F1, F3
HRTX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,564
- Change %
- -14%
- Price
- $0.000000
- Shares after
- 27,936
- Date
- 13 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,564
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
Footnote F3
The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
Footnote F4
The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).